Table 1.

Baseline characteristics of all patients, stratified by treatment group.

		CONV [n = 43]	FL-IFX [n = 48]	p-value
Age at diagnosis, years		14.1 [11.5–16.3]	15.0 [11.8–16.5]	0.266
Male gender		24 [53%]	23 [49%]	0.596
Height, cm		161 [143–172]	166 [153–175]	0.154
Weight, kg		46.3 [30.5–55.0]	47.3 [36.4–56.8]	0.332
wPCDAI		57.5 [47.5–72.5]	57.5 [47.5–67.5]	0.886
CRP, mg/L		37.0 [22.0–65.5]	29.5 [8.8–46.8]	0.053
ESR, mm/h		32.5 [22.0–63.5]	34.0 [26.0–46.0]	0.910
SES-CD		15.0 [8–22]	15.0 [9–21]	0.843
Faecal calprotectin, µg/g		1128 [IQR 592–1670]	1114 [IQR 886–1800]	0.553
Paris classification
Age at diagnosis	<10 years	7 [16%]	4 [8%]	0.481
	10–17 years	32 [74%]	38 [79%]
	17–40 years	4 [9%]	6 [13%]
Disease location	L1	10 [23%]	12 [25%]	0.802
	L2	11 [26%]	11 [23%]
	L3	22 [51%]	24 [50%]
	Isolated L4	—	1 [2%]
Upper disease location	No upper GI	22 [51%]	28 [58%]	0.789
	L4a	19 [44%]	18 [38%]
	L4b	2 [5%]	2 [4%]
Disease behaviour	B1	38 [88%]	45 [94%]	0.366
	B2	5 [12%]	3 [4%]
	B3	–	–
	B2B3	–	–
Perianal diseaseb		9 [21%]	5 [10%]	0.165
Growth delay		2 [0.5%]	1 [0.2%]a	0.509

Data are n [%] or median [IQR]. Significance was assessed using the Mann–Whitney U-test for numerical variables or chi-square test for categorical variables; p < 0.05 was considered significant. FL-IFX, first-line infliximab; CONV, conventional induction therapy; wPCDAI, weighted paediatric Crohn’s disease activity index [range, 0‒125]; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; SES-CD, simple endoscopic score for Crohn’s disease [range, 0–60].

^aOne missing data point.

^bPerianal disease was defined as inactive fistula, skin tags or anal fissures.